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Abstract
Detectable measurable residual disease (MRD) is a key prognostic factor in both acute lymphoblastic leukemia (ALL) and
acute myeloid leukemia (AML) patients. Thus, we conducted a survey in EBMT transplant centers focusing on pre- and
post-allo-HCT MRD. One hundred and six centers from 29 countries responded. One hundred had a formal strategy for
routine MRD assessment, 91 for both ALL and AML. For ALL (n= 95), assessing MRD has been routine practice starting
from 2010 (range, 1990–2019). Techniques used for MRD assessment consisted of PCR techniques alone (n= 27),
multiparameter flow cytometry (MFC, n= 16), both techniques (n= 43), next-generation sequencing (NGS)+ PCR (n= 2),
or PCR+MFC+NGS (n= 7). The majority of centers assessed MRD every 2–3 months for 2 (range, 1-until relapse) years.
For AML, assessing MRD was routine in 92 centers starting in 2010 (range 1990–2019). Assessment of MRD was by PCR
(n= 23), MFC (n= 13), both PCR and MFC (n= 39), both PCR and NGS (n= 3), and by all three techniques (n= 14). The
majority assesses MRD for AML every 2–3 months for 2 (range, 1-until relapse) years. This survey is the first step in the aim
to include MRD status as a routine registry capture parameter in acute leukemia.
Introduction
Over the last decade, persistence of detectable measurable
residual disease (MRD) after intensive chemotherapy has
proven to be a key prognostic factor in adult patients with
acute leukemia. Specifically, in the setting of acute lym-
phoblastic leukemia (ALL), MRD monitoring has become
an important parameter to guide therapeutic strategy
including indication or not of performing an allogeneic
hematopoietic stem cell transplantation (allo-HCT) in first
complete remission [1, 2]. Indeed, in a recent meta-analysis
achievement of MRD negativity was strongly associated
with better overall survival (OS) [3]. Similarly, in the set-
ting of acute myeloid leukemia (AML), persistence of
detectable MRD after induction and/or consolidation che-
motherapy has been identified as a strong prognostic factor
in patients with NPM1-wt standard-risk AML patients [4] as
well as in NPM1-mutated patients [5, 6]. Based on these
observations, recent trials have included MRD data to
allocate patients or not to allo-HCT [7], while the 2017
EuropeanLeukemiaNet (ELN) recommendations introduced
the concept of CR without MRD as a response criteria for
AML [8].
Despite allo-HCT remaining one of the most potent anti-
leukemic strategy in patients with acute leukemia [9, 10],
several recent studies have demonstrated that persistent
detectable MRD at transplantation remains a key prognostic
factor in both ALL and AML patients [11]. Specifically, in
children with ALL, pretransplant MRD ≥10−3 (assessed
with quantitative polymerase chain reaction (qPCR)
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detecting leukemic clone-specific T-cell-receptor (TCR)/
Immunoglobulin (Ig) gene rearrangements) was associated
with a high risk of relapse leading to worse OS [12]. In the
AML setting, pretransplant MRD (assessed by multi-
parameter flow cytometry (MFC)) ≥0.01% was associated
with higher risk of relapse and lower OS even after
adjusting with disease status at transplantation and ELN risk
group [13]. Interestingly, the negative impact of persistent
MRD (at least when assessed by MFC) was comparable in
patients with MRD levels >1% and those with MRD levels
<0.01%, suggesting that any level of persistent MRD was of
poor prognosis [14]. Confirming these findings, a recent
meta-analysis including data from 19 articles reported
between 2005 and 2016 demonstrated that detectable MRD
(regardless of MRD methodology, MRD threshold, and
conditioning regimen intensity) at transplantation predicted
for higher relapse incidence and worse OS in allo-HCT
patients [15]. Interestingly, detectable MRD has remained
predictive of allo-HCT outcome in patients with monosomal
karyotype (which is associated with a particularly poor
prognosis by itself [16]) [17]. Thus, incorporating pre-
transplant MRD as an additional parameter in large trans-
plant registry databases, though challenging, is of special
importance. Accordingly, several reports from the ALWP of
the EBMT have evidenced higher risk of relapse and worse
transplantation outcomes in patients with detectable MRD
at transplantation in various transplantation setting [18–23].
Importantly, latest studies have unraveled that post-
transplant MRD re-appearance in patients with acute leu-
kemia was associated with grim outcomes [24].
Specifically, in the ALL-BFM-SCT 2003 Trial, MRD load
>10−4 leukemic cells after all-HCT predicted for high
relapse incidence at any time point after transplantation.
However, interestingly, the predictive value of MRD posi-
tivity was lower on day 30 after transplantation than
thereafter [25]. Similarly, Wethmar et al. observed that
posttransplant residual/relapsing MRD (assessed by qPCR
targeting disease-specific genetic rearrangements and/or
lineage-sorted donor cell chimerism) in ALL patients pre-
dicted for a high relapse incidence and poor OS [26].
In the AML setting, Pozzi et al. demonstrated that WT1
overexpression (defined >100 messenger copies/104
ABL1) after allo-HCT was the strongest predictor of
relapse in AML patients [27]. Interestingly, among patients
with posttransplant WT1 overexpression OS was improved
in patients who received preemptive donor lymphocyte
infusions. In the study from the Fred Hutchinson Cancer
Center, pretransplant MRD (assessed by MFC) was asso-
ciated with grim outcomes regardless of whether or not
MRD was cleared on day 28 after allo-HCT [24]. How-
ever, two patients MRD negative at allo-HCT who were
MRD positive on day 28 died of AML relapse before day
28 [24]. Thus, capturing posttransplant MRD data at key
time points is also of major interest for transplantation
registries.
Several MFC and molecular biology approaches have
been developed to assess MRD in patients with acute leu-
kemia [28]. Their sensitivity ranges from 10−3 to 10−6. In
ALL, qPCR detecting leukemic clone-specific TCR/Ig gene
rearrangements can be used in ~90% of the patients [1].
MCF can also be used in >90% of the patients [1]. In AML
while qPCR methods can only be used to quantify mole-
cular markers and gene fusions such as BCR/ABL, NPM1,
CBFB-MYH11, RUNX1-RUNX1T1, PML-RARA or
KMT2A-AFF4, MCF and next-generation sequencing
(NGS) methods are considered as more universal [29, 30].
However, they generally have a lower sensitivity. Given its
even lower sensitivity, WT1 expression is currently con-
sidered to be a suboptimal MRD marker that should be used
only if other techniques are not available [29].
As a first step aimed at including pre- and posttransplant
MRD status as routine registry capture parameters [31], we
conducted a survey among European Blood and Marrow
Transplantation Society (EBMT)-affiliated centers focused
on MRD assessment pre- and post-allo-HCT for patients
with either AML or ALL.
Methods
A total of 325 EBMT-affiliated centers were contacted by e-
mail to invite them to complete an online survey assessing
how MRD was assessed in their center. Specifically, the
questionnaire surveyed the location of MRD analysis (in-
house, outsourced, or both), the methodology (PCR, FCM,
NGS, or combination of these techniques), cut-off points for
MRD negativity, and timing as well as duration of MRD
monitoring after transplantation for both AML and ALL.
The detailed survey is provided in Supplementary Table 1.
The board of the acute leukemia working party of the
EBMT approved this survey.
Results
One hundred and six centers out of 325 (33%) contacted
centers responded to the survey (Fig. 1). Among the 219
centers that did not answer to the survey, 189 (88%) and
170 (78%) centers reported data on pretransplant MRD for
AML or ALL patients transplanted in 2018, respectively.
Among the 106 centers that answered to the survey, the
figures were 95 (91%) and 92 (87%), respectively.
Responding centers were from 29 countries, including Italy
(n= 23), Germany (n= 12), France (n= 11), Spain (n= 8),
and Belgium (n= 5). Responding centers were of various
sizes reporting a median of 1–97 allogeneic or autologous
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transplantation for acute leukemia per year from 2014 to
2018. Out of the 106 centers that answered the survey, 48
performed <100 transplants and 58 more than 100 trans-
plants from January 2014 to December 2018. Among cen-
ters that performed 100 or more transplants, 55% and 78%
of the centers performed the MRD testing only in their
hospital for ALL and AML, respectively. Among smaller
size centers, the figures were 45% and 68%, respectively.
There was no significant difference between the methods
used according to center size (data not shown). One hun-
dred centers had a formal strategy for routine MRD
assessment for both AML and ALL (n= 91), ALL only
(n= 4), and AML only (n= 1). Four centers performed
routine MRD assessments but failed to answer the
remaining survey questions. In contrast, six centers reported
not having a formal strategy for routine MRD assessment,
including two centers from Algeria, two from Germany, one
from Brazil, and one from Saudi Arabia.
Acute lymphoblastic leukemia
Ninety-five centers indicated that, for ALL, assessing MRD
has been routine practice starting from 1990 to 2019 (median,
2010). Of these, 48 (51%) do it in-house, 20 (21%) out-
source, and 27 (28%) use both options. Twenty-seven centers
assess MRD by PCR, 16 by MFC, 43 use both, 2 use PCR
and NGS, and 7 use all three techniques (Fig. 2a). By PCR
(n= 79), MRD negativity is regarded as 10−5 in 40, 10−4 in
18 and 10−6 in 7, and 10−3 in 5 centers (Fig. 2b). The data
were missing for six centers, and three centers answered that
the threshold depended on which marker was used. For those
assessing MRD by MFC (n= 66), MRD negativity threshold
is 10−4 in 37, 10−5 in 13, 10−3 in 8, 10−6 in 4, and 10−2 in 1
centers. The data were missing for two centers and one center
answered that the threshold depended on which marker was
used. For those centers assessing MRD by NGS (n= 9),
MRD negativity is regarded as 10−3 in 2 and 10−4 in 2
centers. The data were missing for three centers and two
centers answered that the threshold depended on which
marker was used.
The majority of centers assess MRD every 2–3 months
post-allo-HCT (n= 63) or once every 3 months post-allo-
HCT (n= 9). The duration of post-allo-HCT MRD assess-
ment was 1 year in 19 centers, 2 years in 36 centers, 5 years
in 10 centers, or until relapse in 20 centers. Less frequent
answers included depending on patient (n= 2), other (n= 2),






































































































































































Fig. 1 Number of responding
centers per country. Number of
centers responding to the MRD
survey (black bars) according to
the number of centers reporting
allo-HCT (gray bars) to the



















Fig. 2 MRD assessment in ALL. a Methods used for MRD assess-
ment in ALL. b Cut-off point regarding as negative MRD according to
the technique used.
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study regulations (n= 1), not routinely done after trans-
plantation (n= 1), on demand (n= 1), and missing (n= 1).
Acute myeloblastic leukemia
For AML, assessing MRD was routine in 92 centers starting
from 1990 to 2019 (median, 2010). It has been done in-
house in 67 (74%), outsourced in 9 (10%), and by both in
15 (16%) of centers. The information was missing for one
patient. Assessment of MRD was performed by PCR only
in 23 centers, by MFC only in 13, by both PCR and MFC in
39, by PCR and NGS in 3, and by all three techniques in 14
centers (Fig. 3a). Using PCR (n= 79), MRD negativity is
regarded as 10−3, 10−4, 10−5, and 10−6 in 3, 22, 28, and 6
centers, respectively. The data were missing for 8 centers
and 12 centers answered that the threshold depended on
which marker was used (Fig. 3b). By MFC (n= 66), MRD
negativity is regarded as 10−3, 10−4, 10−5, and 10−6 in 20,
29, 7, and 4 centers, respectively. The data were missing for
1 center and 5 centers answered that the threshold depended
on which marker was used. Finally, for those centers
assessing MRD by NGS (n= 17), MRD negativity is
regarded as 10−2, 10−3 10−4, 10−5, and 10−6 in 1, 9, 2, 1,
and 1 centers, respectively. The data were missing for 1
center and 2 centers answered that the threshold depended
on which marker was used. The majority assess MRD for
AML every 2–3 months posttransplant (n= 38) or once
every 3 months posttransplant (n= 25). The duration of
post-allo-HCT MRD assessment was 1 year in 15 centers,
2 years in 37 centers, 5 years in 9 centers, until relapse in 22
centers or depending on patients in 4 centers. Less frequent
answers included 3 months (n= 1), according to chimerism
(n= 1), not routinely done except for acute promyelocytic
leukemia (n= 1), on demand (n= 1), or missing (n= 1).
Discussion
As mentioned in the introduction, several techniques have
been used to assess pre- and posttransplant MRD after
transplantation. In ALL, qPCR techniques targeting
antigen-receptor gene rearrangements can be used in >90%
of the patients, with most often a sensitivity of 10−5 [1].
Molecular detection of fusion transcripts (such as BCR/
ABL) can also be used for MRD detection with a high
sensitivity (10−5) but can be biased by the fact that the
number of RNA transcripts per leukemic cell varies among
different leukemic cells. MCF can also be used in >90% of
the patients and can reach a sensitivity of 10−3 to 10−5 [1].
The main advantage of MCF (in comparison to qPCR tar-
geting antigen-receptor gene rearrangements) is that this
technique can provide results in a few hours but the samples
need to be processed relatively quickly after collection (i.e.,
within 3 days at the most to avoid cell death). In ALL
setting, MFC can be affected by posttransplant regeneration
of normal lymphoid cells co-expressing some ALL-type
antigens. Recently, the use of high-throughput methods
(next-generation flow cytometry) allowed processing large
amounts of cells (>107 stained cells) in parallel, sub-
stantially increasing the sensitivity of the technique to 10−5
with a very high applicability (>98%) [32]. Further, recent
studies have suggested a complementary role of combining
qPCR MRD assessment with lineage-specific chimerism
evaluations [26].
In AML, qPCR can only be used for gene fusions such as
BCR/ABL, NPM1, CBFB-MYH11, RUNX1-RUNX1T1,
PML-RARA, or KMT2A-AFF4. In contrast, MFC has a
large applicability (>90% of AML patients) with a good
sensitivity (10−3–10−5) [28]. Two different approaches are
used for assessing MRD with MCF: (1) the leukemia-
associated aberrant immunophenotypes (LAIP) approach,
which identifies LAIP at diagnosis and tracks these in fol-
lowing samples; and (2) the “different-from-normal”
approach, which is based on the identification of aberrant
differentiation/maturation profiles even without a diagnostic
phenotype for reference. Since the LAIP approach can be
affected by phenotypic shift of the leukemic cells, ELN
experts recommend that both approaches are combined to
follow MRD in AML by FCM [29]. NGS is also becoming
an important tool for MRD monitoring in AML. This
technique is applicable to virtually all AML patients but the


















Fig. 3 MRD assessment in AML. a Methods used for MRD
assessment in AML. b Cut-off point regarding as negative MRD
according to the technique used.
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approaches. The sensitivity of this approach is generally
lower than what can be achieved with qPCR or MFC but
this technique also allows the identification of leukemic sub
clones [33].
As a first step aimed at including pre- and posttransplant
MRD status as routine registry capture parameters, we
conducted a survey among EBMT-affiliated centers focused
on MRD assessment pre- and post-allo-HCT for patients
with either AML or ALL. This survey provided useful
information on how MRD is currently assessed in acute
leukemia patients undergoing an allo-HCT.
An initial observation was that among the 106 transplant
centers who responded to the survey, 95 (90%) and 92
(87%) had a formal strategy for routine MRD assessment in
ALL and/or AML, respectively. This indicates the
increasing routine use of MRD data in the management of
transplant patients. However, although centers from 29
different countries took part in the survey, it is likely that
there was some participation bias in favor of centers
assessing MRD, these probably being more likely to answer
the survey than centers not assessing MRD.
In ALL patients, MRD was most frequently assessed by
PCR techniques (74% of centers) either alone (28% of
centers) or in combination with flow cytometry (45% of
centers). In contrast, MCF was the sole method of MRD
assessment in 16% of centers.
Similarly to that observed in ALL patients, among AML
patients, MRD was most frequently assessed by PCR
techniques (67% of centers) either alone (25% of centers) or
in combination with flow cytometry (42% of centers). In
contrast, MCF was the sole method of MRD assessment in
16% of centers.
In concordance with data from the literature, the median
sensitivity reported by the centers was a log higher for PCR
techniques (10−5) than for MFC methods (10−4). Impor-
tantly, there was a considerable variation from center to
center in the cut-off point for MRD negativity ranging from
10−2 to 10−6. This suggests that future collection of MRD
registry data should ideally not be restricted to dichotomous
responses such as MRD positivity or not, and that ques-
tionnaires should allow the recording of the level of MRD
positivity or the cut-off for MRD negativity (in the case of
MRD negative patients). This will likely increase the pre-
dictive value of pretransplant MRD status on relapse risk
and OS above what has been observed with MRD positivity
as currently ascertained in the EBMT registry database.
Further, having these data in the registry will also benefit to
study assessing the impact of prophylactic intervention such
as posttransplant immunosuppression discontinuation,
donor lymphocyte infusion, or targeted low-intensity
therapies on leukemia progression [34–39].
In summary, these data indicate that assessing MRD for
both ALL and AML has become routine practice in close to
100 EBMT transplant centers, with 50–74% of them
establishing the assay in-house. The assessment technique
and threshold values varied between centers. In these cen-
ters, MRD status is assessed every 2–3 months for a median
of 2 years after transplantation or until relapse. Based on
these consideration, one could propose that AL transplant
registries could collect MRD data pretransplant on day 40,
100, 180, and 365 after transplantation. These data might
consist of capturing the MRD level, the technique used, the
sensitivity of the technique, and the cell type assessed (bone
marrow, peripheral blood. or lineage-specific cells).
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